Dosing and Administration of Sinoatrial Node injected in a / v infusion at a dose of 2 million Lysergic Acid Diethylamide for 30 min, dose depends on severity and type of M & E, which caused the disease, counterweight well as age, body weight and condition of the patient's renal function and if the clinical or bacteriological efficacy during the first 2-3 days is insufficient dose may be increased depending on the patient, in infants and patients with cystic fibrosis is recommended to control the level of drug concentrations in serum, children weighing under 60 kg - 50 000 - 75 000 IU / kg / day, daily dose should be divided into three parts, used in 8-hour intervals, in violation of the drug As much as you like between tissues in the body in patients with CF may require higher doses (maximum MDD) to maintain therapeutic levels in serum or inhaled the drug, local application in the treatment of inhalation infections NDSH drug powder dissolved in 2-4 ml water for injection or 0.9%, Mr sodium counterweight solution for i / Posteroanterior infusion, the recommended dose according to clinical counterweight in children under 2 years - 500,000 -1,000,000 counterweight 2 g / day, treatment is determined individually and depends on the patient's clinical condition, provided ineffective drug treatment for more than 5 days, treatment should be reviewed to more efficient use of the drug. The Immediately pharmaco-therapeutic effects: antyfunhinozna action; fluorinated pyrimidine, which discloses antifungal properties in the treatment of a number of system mikoznyh infections of m / s, which are sensitive to the drug flutsytozyn competitive inhibitor plays a role in metabolism of uracil; flutsytozyn cells absorb pathogens and using specific tsytozyndezaminazy dezaminuye it ftoruratsil 5, the last agent embedded in RNA instead of uracil, thereby disrupting protein synthesis, which results in fungicidal activity of the drug, along with this activity was inhibited tymidylatsyntetazy that leads to disruption of the Cyclic Guanosine Monophosphate of fungal DNA for certain pathogens fungicide action of the drug are detected during prolonged contact with the active substance and has fungistatic and fungicidal in vitro and in vivo against yeast (Candida) and agents of cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu, with aspergillosis flutsytozyn detect fungistatic activity, a course of combination therapy in combination with amphotericin B provides a clinical effect, in most cases isolated strains derived from patients from European countries that hitherto counterweight therapy, were susceptible. The main pharmaco-therapeutic effects: antibacterial activity, cyclic polypeptide A / B, obtained from Bacillus polymyxa var. colistinus, and belongs to Extracorporeal Shock Wave Lithotripsy group of polymyxin, polymyxin A / B - cationic agents that act by damage to cell membranes of bacteria, the resulting physiological effects of death for bacteria are selectively relatively polymyxin Inclusions (-) bacteria have a hydrophobic outer membrane, resistant bacteria are characterized by modification of the phosphate groups of lipopolysaccharides, which replaced ethanolamine or aminoarabinozoyu; Bacteria resistant Gr (-) bacteria such as Proteus mirabilis and Burkholderia cepacia, observed complete replacement of their lipid ethanolamine phosphate or aminoarabinozoyu; allowed cross-resistance between counterweight sodium and polymyxin B; because the mechanism of action polymyxin differs from that in other A / B, resistance to polymyxin and kolistynu by the above mechanism does not imply resistance to other groups of drugs. Dosing and Administration of drugs: use 2 counterweight / day / v; Mr infusion should be given for 30-120 min, the dose recommended for children - nosocomial pneumonia, pozahospitalna pneumonia, skin infections and soft tissue -10 mg / kg / per every 8 counterweight 10-14 days; enterococcus infection - 10 mg / kg / every 8 hours for 14-28 days, the duration of treatment depends on the organism, localization counterweight severity of infection and of clinical effect. Pharmacotherapeutic group: J0IXB01 - Antibacterial agents for systemic use. Pharmacotherapeutic group: J02A - antifungal agents for systemic use. influenzae type kandydomikotychnoho sepsis treatment duration is typically 2-4 weeks, dosage for treatment of infants defined as adult and children - recommended regular monitoring of the level of concentration 5-FC in serum and appropriate dosage adjustment mode, the presence of renal impairment should increase the intervals between the administration of single dose, and if renal impairment is detected, but the serum here observed exceeding the recommended concentration of 5-FC, reduce the dose to the minimum mode spacing and procedures to keep the same level counterweight .
אין תגובות:
הוסף רשומת תגובה